Try our Advanced Search for more refined results

US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

September 23, 2020

JANSSEN PHARMACEUTICALS, INC. et al v. MYLAN LABORATORIES LIMITED et al

Track this case

Case Number:

2:20-cv-13103

Court:

New Jersey

Nature of Suit:

Patent - Abbreviated New Drug Application(ANDA)

Judge:

Evelyn Padin

Firms

Companies

Sectors & Industries:

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. May 23, 2023

    Janssen Prevails In Patent Battle With Mylan Over Generics

    A New Jersey federal judge has ruled that Mylan cannot pursue a generic version of Janssen's schizophrenia drug Invega Trinza, finding that although the patent for Trinza has expired, Mylan's generic would cause physicians to infringe another Janssen patent covering the drug's dosing regimen, according to an order unsealed Tuesday.

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login